Zhao Ran, Yang Shengjie, Li Dan, Liu Longtao, Xing Yanwei, Wu Min
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.
Evid Based Complement Alternat Med. 2021 Jul 22;2021:8663022. doi: 10.1155/2021/8663022. eCollection 2021.
Hypertension is a serious global public health problem, and its incidence increases with age. Research has suggested that multiple antihypertensive prescriptions may be harmful to older individuals with hypertension. Baduanjin, a widely practiced physical activity in China, has been used as an adjuvant therapy to antihypertensive treatment in older individuals with hypertension. Therefore, the aim of the current study is to investigate whether Baduanjin exercise could reduce the need for antihypertensive medications in older patients.
This single-center, open, randomized controlled trial will be conducted in China. Seventy eligible participants will be randomly assigned to either the 12-week Baduanjin exercise group or the 12-week aerobic exercise group (5 times a week), at a ratio of 1 : 1. The primary outcome will include the proportion of participants who reduce their antihypertensive medications. The secondary outcomes will include the changes in mean office systolic and diastolic pressure, 24-h ambulatory blood pressure, health-related quality of life (based on SF-36), and gut microbiota composition. The results of this study will provide powerful evidence for the use of Baduanjin as an adjuvant therapy for antihypertensive medication reduction in older people with hypertension and therefore find the best treatment for hypertension. This trial is registered in the Chinese Clinical Trials Registry (ChiCTR1900024429).
高血压是一个严重的全球公共卫生问题，其发病率随年龄增长而增加。研究表明，多种抗高血压药物处方可能对老年高血压患者有害。八段锦是在中国广泛开展的一项体育活动，已被用作老年高血压患者抗高血压治疗的辅助疗法。因此，本研究的目的是调查八段锦锻炼是否可以减少老年患者抗高血压药物的使用需求。
本单中心、开放、随机对照试验将在中国进行。70名符合条件的参与者将以1∶1的比例随机分配到12周八段锦锻炼组或12周有氧运动组（每周5次）。主要结局将包括减少抗高血压药物的参与者比例。次要结局将包括诊室平均收缩压和舒张压、24小时动态血压、健康相关生活质量（基于SF-36）和肠道微生物群组成的变化。本研究结果将为八段锦作为老年高血压患者减少抗高血压药物使用的辅助疗法提供有力证据，从而找到治疗高血压的最佳方法。本试验已在中国临床试验注册中心注册（ChiCTR1900024429）。
